Market Overview

Why Redhill Biopharma's Stock Is Trading Higher Today


Redhill Biopharma (NASDAQ: RDHL) shares are trading higher on Friday, after the company received FDA approval for its coronavirus clinical study with Opaganib in the U.S.

Redhill Biopharma is a specialty company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults.

Redhill Biopharma shares were trading up 7.86% at $7.05 at time of publication. The stock has a 52-week high of $9.12 and a 52-week low of $3.26.

Related Links:

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

Moderna, Lonza Strike Deal To Manufacture Up To 1 Billion Doses Of Coronavirus Vaccine Candidate Annually


Related Articles (RDHL)

View Comments and Join the Discussion!

Posted-In: why it's movingNews FDA